<?xml version="1.0"?>
<rss version="2.0" xmlns:prism="http://purl.org/rss/1.0/modules/prism/">
  <channel>
    <title>AMA Publishing Group: Diabetic Retinopathy Topic Collection</title>
    <link>http://pubs.jamanetwork.com/</link>
    <description>
    </description>
    <language>en-us</language>
    <pubDate>Thu, 02 May 2013 00:00:00 GMT</pubDate>
    <lastBuildDate>Thu, 02 May 2013 16:45:24 GMT</lastBuildDate>
    <generator>Silverchair</generator>
    <managingEditor>editor@pubs.jamanetwork.com</managingEditor>
    <webMaster>webmaster@pubs.jamanetwork.com</webMaster>
    <item>
      <title>Intravitreal Fasudil Combined With Bevacizumab for Persistent Diabetic Macular Edema: A Novel Treatment</title>
      <link>http://pubs.jamanetwork.com/article.aspx?articleID=1682369</link>
      <pubDate>Thu, 02 May 2013 00:00:00 GMT</pubDate>
      <author>Ahmadieh H, Nourinia R, Hafezi-Moghadam A. </author>
      <description>&lt;span class="paragraphSection"&gt;Despite recent advances in pharmacotherapy for diabetic macular edema (DME), satisfying anatomical and visual results are not always achieved. Improved understanding of the mechanisms underlying diabetic retinopathy may pave the way for new treatment modalities for DME that is refractory to current therapies.&lt;/span&gt;</description>
      <prism:startingPage xmlns:prism="prism">1</prism:startingPage>
      <prism:endingPage xmlns:prism="prism">2</prism:endingPage>
      <prism:doi xmlns:prism="prism">10.1001/jamaophthalmol.2013.143</prism:doi>
      <guid>http://pubs.jamanetwork.com/article.aspx?articleID=1682369</guid>
    </item>
  </channel>
</rss>